Reviewing Apyx Medical (NASDAQ:APYX) and Abiomed (NASDAQ:ABMD)
Reviewing Apyx Medical (NASDAQ:APYX) and Abiomed (NASDAQ:ABMD)
Apyx Medical (NASDAQ:APYX – Get Rating) and Abiomed (NASDAQ:ABMD – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.
阿皮克斯醫療(納斯達克：APYX-GET評級)和艾彼德(納斯達克：ABMD-GET評級)都是醫療公司，但哪一家更好？我們將根據兩家公司的分析師建議、機構持股、盈利能力、估值、風險、股息和收益的強弱對它們進行比較。
Institutional and Insider Ownership
機構和內部人持股
65.6% of Apyx Medical shares are owned by institutional investors. Comparatively, 94.5% of Abiomed shares are owned by institutional investors. 11.6% of Apyx Medical shares are owned by company insiders. Comparatively, 2.5% of Abiomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Apyx Medical 65.6%的股份由機構投資者持有。相比之下，Abied 94.5%的股份由機構投資者持有。Apyx Medical 11.6%的股份由公司內部人士持有。相比之下，Abied 2.5%的股份由公司內部人士持有。強大的機構持股表明，捐贈基金、大型基金經理和對衝基金相信，從長期來看，一隻股票的表現將好於大盤。
Risk and Volatility
風險和波動性
Apyx Medical has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Abiomed has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
Apyx Medical的貝塔係數為1.3，表明其股價的波動性比標準普爾500指數高30%。相比之下，Abied的貝塔係數為1.4，這表明其股價的波動性比標準普爾500指數高40%。
Analyst Recommendations
分析師建議
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Apyx Medical | 0 | 1 | 3 | 0 | 2.75 |
| Abiomed | 0 | 5 | 1 | 0 | 2.17 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 阿皮克斯醫療 | 0 | 1 | 3 | 0 | 2.75 |
| Abied | 0 | 5 | 1 | 0 | 2.17 |
Apyx Medical presently has a consensus target price of $6.00, indicating a potential upside of 72.91%. Abiomed has a consensus target price of $355.60, indicating a potential downside of 6.67%. Given Apyx Medical's stronger consensus rating and higher probable upside, equities research analysts clearly believe Apyx Medical is more favorable than Abiomed.
Apyx Medical目前的共識目標價為6.00美元，潛在上行空間為72.91%。Abied的共識目標價為355.60美元，表明潛在下跌6.67%。鑑於Apyx Medical更強勁的共識評級和更高的可能上行空間，股票研究分析師顯然認為Apyx Medical比Abied更有利。
Profitability
盈利能力
This table compares Apyx Medical and Abiomed's net margins, return on equity and return on assets.
此表比較了Apyx Medical和Abied的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Apyx Medical | -39.28% | -39.82% | -31.06% |
| Abiomed | 24.84% | 14.77% | 13.32% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 阿皮克斯醫療 | -39.28% | -39.82% | -31.06% |
| Abied | 24.84% | 14.77% | 13.32% |
Earnings and Valuation
收益和估值
This table compares Apyx Medical and Abiomed's top-line revenue, earnings per share and valuation.
此表比較了Apyx Medical和Abied的營收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Apyx Medical | $48.52 million | 2.47 | -$15.17 million | ($0.56) | -6.20 |
| Abiomed | $1.03 billion | 16.65 | $136.51 million | $5.82 | 65.47 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 阿皮克斯醫療 | 4,852萬美元 | 2.47 | -1,517萬元 | ($0.56) | -6.20 |
| Abied | 10.3億美元 | 16.65 | 1.3651億美元 | $5.82 | 65.47 |
Abiomed has higher revenue and earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Abiomed, indicating that it is currently the more affordable of the two stocks.
Abied的收入和收益比Apyx Medical更高。Apyx Medical的市盈率低於Abied，表明它目前是兩隻股票中更負擔得起的一隻。
Summary
摘要
Abiomed beats Apyx Medical on 10 of the 14 factors compared between the two stocks.
Abied在兩隻股票比較的14個因素中有10個超過了Apyx Medical。
About Apyx Medical
關於阿皮克斯醫療公司
(Get Rating)
(獲取評級)
Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
阿皮克斯醫療公司是一家以能源為基礎的醫療技術公司。該公司致力於開發、製造和營銷一系列電外科產品和技術，以及用於世界各地醫生、手術中心和醫院辦公室的相關醫療產品。它通過以下部門運營：先進能源和原始設備製造(OME)。該公司由安德魯·馬克裏德斯於1978年創立，總部設在佛羅裏達州克利爾沃特。
About Abiomed
關於Abied
(Get Rating)
(獲取評級)
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
Abied，Inc.從事醫療設備的研究、開發和銷售，以幫助或取代衰竭心臟的泵浦功能。它還為心力衰竭患者提供持續的護理。該公司提供Impella 2.5，這是一種集成了發動機和傳感器的經皮微型心臟泵；Impella CP，一種供介入心臟科醫生在導管實驗室支持患者以及心臟外科醫生在心臟外科套件中使用的設備。它還提供Impella 5.0、Impella LD和Impella 5.5，這是一種具有集成電機和傳感器的經皮微創心臟泵，主要用於心臟手術室；Impella RP是一種基於經皮導管的軸流泵；Impella SmartAssist平臺包括光學傳感器技術，可以改進泵的定位，並使用算法來改進斷奶過程中的本地心臟評估；Impella Connect是一種基於雲的技術，可以為醫生和醫院工作人員安全地遠程查看自動Impella控制器；以及Oxy-1 System，這是一種便攜式外部呼吸輔助設備。此外，該公司正在開發Impella ECP，這是一種每分鐘血流超過3升的泵；Impella XR Sheath，一種可以膨脹和回縮的鞘，允許小孔進入，並與Impella心臟泵一起關閉；Impella BTR，一種集成了發動機和傳感器的經皮微型心臟泵；以及PreCARDIA，一種導管安裝的上腔靜脈治療系統，旨在快速治療急性失代償性心力衰竭。Abied，Inc.通過直銷和臨牀支持人員在德國、法國、美國、日本、歐洲、加拿大、拉丁美洲、亞太地區和中東銷售其產品。該公司成立於1981年，總部設在馬薩諸塞州丹佛斯。截至2022年12月22日，Abied, 股份有限公司是強生的子公司。
Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿皮克斯醫學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Apyx Medical和相關公司的最新新聞和分析師評級的每日簡要摘要。